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COMMENTARY

Is telemedicine the answer to rural
expansion of medication treatment for opioid
use disorder? Early experiences in the feasibility
study phase of a National Drug Abuse
Treatment Clinical Trials Network Trial
Yih‑Ing Hser1* , Allison J. Ober2, Alex R. Dopp2, Chunqing Lin3, Katie P. Osterhage4, Sarah E. Clingan1,
Larissa J. Mooney1,5, Megan E. Curtis1, Lisa A. Marsch6, Bethany McLeman6, Emily Hichborn6, Laurie S. Lester6,
Laura‑Mae Baldwin4, Yanping Liu7, Petra Jacobs7 and Andrew J. Saxon8,9

Abstract
Telemedicine (TM) enabled by digital health technologies to provide medical services has been considered a key
solution to increasing health care access in rural communities. With the immediate need for remote care due to the
COVID-19 pandemic, many health care systems have rapidly incorporated digital technologies to support the delivery
of remote care options, including medication treatment for individuals with opioid use disorder (OUD). In responding
to the opioid crisis and the COVID-19 pandemic, public health officials and scientific communities strongly support
and advocate for greater use of TM-based medication treatment for opioid use disorder (MOUD) to improve access
to care and have suggested that broad use of TM during the pandemic should be sustained. Nevertheless, research
on the implementation and effectiveness of TM-based MOUD has been limited. To address this knowledge gap, the
National Drug Abuse Treatment Clinical Trials Network (CTN) funded (via the NIH HEAL Initiative) a study on Rural
Expansion of Medication Treatment for Opioid Use Disorder (Rural MOUD; CTN-0102) to investigate the implementa‑
tion and effectiveness of adding TM-based MOUD to rural primary care for expanding access to MOUD. In preparation
for this large-scale, randomized controlled trial incorporating TM in rural primary care, a feasibility study is being con‑
ducted to develop and pilot test implementation procedures. In this commentary, we share some of our experiences,
which include several challenges, during the initial two-month period of the feasibility study phase. While these chal‑
lenges could be due, at least in part, to adjusting to the COVID-19 pandemic and new workflows to accommodate
the study, they are notable and could have a substantial impact on the larger, planned pragmatic trial and on TMbased MOUD more broadly. Challenges include low rates of identification of risk for OUD from screening, low rates of
referral to TM, digital device and internet access issues, workflow and capacity barriers, and insurance coverage. These
challenges also highlight the lack of empirical guidance for best TM practice and quality remote care models. With TM
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expanding rapidly, understanding implementation and demonstrating what TM approaches are effective are critical
for ensuring the best care for persons with OUD.
Keywords: Telemedicine, Opioid use disorder, Medication for opioid use disorder, Rural community, Primary care,
Implementation, COVID-19

Background
Telemedicine (TM) enabled by digital health technologies to provide medical services has been considered a
key solution to increasing health care access in rural communities [1, 2]. However, despite the impact of the opioid
crisis on rural communities and the limited resources in
these areas to provide effective treatment to all those in
need, the use of TM to treat opioid use disorder (OUD)
has been limited. Notable implementation barriers
include TM regulations (e.g., licensing, reimbursement)
and contextual factors inherent to rural communities
such as broadband availability. With the immediate need
for remote care due to the COVID-19 pandemic, many
TM restrictions have been waived, and health care systems have rapidly modified their practice to include digital technologies (e.g., telephone, video chat) for remote
primary care and specialty services, including medication
treatment for OUD (MOUD). In recent years and even
more so now, in concert with the rapid uptake of TM,
many articles and commentaries [3, 4] have been advocating for wider and greater use of TM to improve access
to health care and have suggested that broad use of TM
during the pandemic should be sustained. While increasing access to care through TM for people with OUD,
especially in rural areas severely impacted by the opioid
crisis is desirable, research on the implementation and
effectiveness of TM-based MOUD is limited.
To address this gap in the literature, prior to the
COVID-19 pandemic, we conceived of a study designed
to address the need for greater access to MOUD by
incorporating the option for TM services delivered by an
external MOUD provider for patients in rural primary
care clinics. Since the pandemic, TM uptake has been
rapid, including the use of TM for primary care and, in
some rural clinics, TM for MOUD. Even with changes
in patient flow in healthcare systems and the unexpected, abrupt introduction of TM in these settings, the
need to study the feasibility and effectiveness of TM for
MOUD remains. Thus, despite changes in the TM policy
and implementation landscape due to the pandemic, we
began the feasibility phase of our study. In this article,
we share our experiences, including some of the challenges we encountered, during the initial period of the
feasibility study. We expect some of these challenges
will be overcome later in the study and perhaps after.
Nevertheless, there is an immediate need to understand

early challenges, given the unprecedented rapid changes
in models of healthcare delivery due to the pandemic
and a number of clinics beginning to implement TM
without implementation guidance or evidence about
effectiveness.

Main text
The Project: Rural Expansion of Medication Treatment
for Opioid Use Disorder

MOUD approved by the U.S. Food and Drug Administration (FDA) are effective and indeed life-saving, but
despite national efforts to increase availability through
office-based opioid treatment (OBOT) programs, uptake
remains slow. Rural communities are of particular concern, as they suffer disproportionately from the opioid
crisis [5, 6], but have limited access to MOUD services.
In 2015 the overdose death rates for rural areas surpassed
the death rate for urban or suburban areas [7]. People
living in rural areas face a number of barriers in accessing MOUD, including a limited number of clinics that
provide MOUD, a shortage of providers who prescribe
opioid treatment medications, long distances to travel
to their opioid treatment providers, and stigma associated with opioid use disorder treatment-seeking in local
communities [1]. Additionally, economic distress, older
populations, and social isolation play significant roles in
opioid addiction in rural communities [8, 9]. There is a
need to identify and study effective ways to expand treatment access and improve retention on MOUD in highly
impacted rural areas. TM-based MOUD offers an additional option to the traditional OBOT to increase access
to care.
In responding to the opioid crisis in rural communities, the National Drug Abuse Treatment Clinical Trials
Network (CTN) funded (via the NIH HEAL Initiative) a
study on Rural Expansion of Medication Treatment for
Opioid Use Disorder (Rural MOUD; CTN-0102). The
study aims to investigate the implementation and effectiveness of adding TM-based MOUD to rural primary
care clinics. This 5-year study has two phases. The first
phase is a feasibility study intended to develop and pilot
test the study procedures and evaluate the feasibility
and preliminary outcomes of a care coordination model
that adds TM-based MOUD from a provider external
to the rural clinic by supporting referral and coordination between the clinic and TM provider. The second
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phase is a large-scale pragmatic trial to test the effectiveness of this model. In this commentary, we present early
experiences, including challenges in implementing TMbased MOUD during the first two months of a 6-month
pilot test. The challenges discussed in this article were
observed through the research team’s interaction with
rural primary care clinics and the study TM provider
(a vendor outside of the clinics) during recruitment of
potential study clinics and with the selected study clinics during regular quality assurance (QA) meetings in the
first 2 months of the study. During the clinic site recruitment phase, the study team visited potential sites to discuss study participation with clinic leadership, providers,
and other staff. Additional clinics were recruited after
televideo or telephone interviews. After study start-up,
QA meetings were conducted with participating study
clinics weekly and involved different staff members when
needed and available, most often the clinic’s care coordinator assigned to facilitate the study, clinic MOUD
champion, and/or information technology (IT) staff. The
purpose of these weekly QA calls was to ensure protocol
adherence and identify challenges, given that their identification can suggest quick adjustments in the implementation of TM. A more formal qualitative analysis of
attitudes toward MOUD treatment and TM that includes
interviews and focus groups with staff as well as patients
with OUD across all clinics is currently underway.
The care coordination model between the tm provider
and rural primary care clinic

Primary care is at the core of rural health care systems.
Most rural primary care clinics are in medically underserved areas, facing a workforce shortage and high
demand for care [8–10]. To quickly expand OUD treatment access in rural areas, the study intervention is
designed to facilitate cooperative relationship between
an established, independent TM vendor and the rural
primary care clinics that may or may not have an existing OBOT program [1]. By integrating referral and
coordination procedures with an established TM vendor into clinic workflows, rural health centers may
be able to quickly extend their capacity to serve more
individuals with OUD in their community, which can
lead to improved quality of patient care and healthier
communities.
The study team partnered with an established TM
vendor that could work closely with clinics on referrals
and provide MOUD and behavioral health services (e.g.,
individual or group sessions) as needed. This partnership
allows for rapid study startup, standardized TM delivery,
and potential scale-up if positive results are obtained. At
the time the study was conceived (prior to COVID-19),
using on-site, credentialed clinic providers to provide
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MOUD via TM was often not feasible due to limited TM
infrastructure and waivered providers. Although many
TM restrictions are temporarily in abeyance during the
national emergency caused by COVID-19, clinics still
experience limited resources for MOUD that likely are
not going to change as quickly as needed to address the
ongoing opioid crisis.
The TM vendor chosen for the study provided TM services in 24 states at the time the project started. The vendor provides a comprehensive TM-based program using
video conferencing between patients and their clinicians
for medication prescription and management, behavioral
therapies, and remotely viewed saliva/urine drug screens.
Most importantly, the vendor is flexible in providing services that meet clinics’ and patients’ needs. The study
does not dictate or require clinics to refer all their OUD
patients to the TM vendor but instead encourages collaborative efforts to provide services that best suit patients’
needs. To ensure successful collaboration, a service
delivery protocol was developed between the TM vendor and each clinic to cover the terms of service, including the following: the services desired by the clinic from
the TM provider (e.g., medication treatment for OUD,
behavioral health services for OUD, coverage as needed
when on-site clinicians are not available), referral options
(e.g., warm handoff, online referral, faxed referral), ways
to communicate about patient progress (e.g., regular
clinical updates, direct messaging to EHR, conventional
calls), and plans to address no-shows and dropout from
services. Clinics refer patients to the TM vendor just as
they would for other external services; this means the
TM vendor bills their clinical services directly to relevant insurance/coverage, allowing each organization to
maintain their independence with separate finances and
budgets.
The feasibility study

Seven rural primary care clinics in three states (Maine,
Washington, Idaho) participated in the feasibility phase
of the study. We selected clinics with varying levels
of OBOT capacity (i.e., according to the number of
buprenorphine-prescribing clinicians at the clinic: 0,
1–3, or more than 3) to maximize the opportunity of
observing diverse implementation patterns and issues
that can inform implementation procedures for clinics participating in the pragmatic trial. These findings
will have implications for the larger, pragmatic trial
phase of the study with respect to how an optimal care
coordination model with TM referral and coordination can be shaped or achieved. Despite the onset of
COVID-19 placing tremendous demands on the clinics and their staff, they completed all training needed
for study implementation in just 8 months. Training
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topics included study protocols, data safety, research
ethics, and OBOT, as well as preparation tasks to set
up study-related procedures and establish connections
with research teams and the TM vendor. The first clinic
started the feasibility study in July 2020; by August
2020 the remaining clinics had begun. The feasibility
study lasted for 6 months for each clinic.
Clinics’ motivation for study participation

The study team conducted site visits to potential clinics
during the site recruitment period (pre-COVID-19) to
present and discuss the study and to address questions
from the clinic leadership and staff. Example issues
regarding TM that arose during site visits include
assurance of compatibility of TM with their treatment
philosophies (e.g., whether TM is a patient-centered
approach and whether TM supports harm reduction
or if abstinence is the goal), development and maintenance of remote patient-provider relationships, as well
as resolving perceived or potential competition over
patients with the TM vendor. Motivations for study
participation included the need to address capacity limitations, including a limited number of on-site prescribers with a Drug Enforcement Administration X-waiver
to prescribe buprenorphine, lack of or limited access
to behavioral health services, need for additional help
to address the needs of non-adherent or more complex patients, and a desire to maximize options of care
for patients, particularly when their needs exceeded
the limitations of a physical facility (i.e., transportation, childcare, or work issues that prevent patients
from maintaining appointments in the clinic). Another
motivation mentioned by some clinics was that moving
some of their patients to the study TM vendor would
allow them to see patients who had been on their waitlist for months for OUD treatment or behavioral health
services. One clinic that already had many X-waivered
providers still welcomed the opportunity to incorporate TM into the clinic for the purpose of expanding
capacity to serve additional people with OUD from surrounding communities that may have logistical challenges accessing care.
EarlyChallenges

During the first few months of the feasibility study,
we observed multiple challenges, including low rates
of identification of new patients with OUD through
screening, low rates of referral to TM, digital/internet access issues experienced by patients, challenges
with TM referral and vendor capacity, and insurance
coverage.
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Low rates of identification of new patients with OUD
from universal screening; challenges with OUD diagnosis

To identify patients with OUD who could benefit from
MOUD, participating clinics were asked to screen for
OUD among all adult patients at least once during the
six-month feasibility study period. TAPS (2–3 items for
opioid use) [11] and the DSM-5 checklist for OUD (11
symptoms) [12] were recommended by the study for
screening and diagnosing OUD, respectively, if clinics
did not have other tools in use. Most clinics used the full
TAPS except for two that used DAST-10 [13] and another
that used the ASSIST [14]. All clinics used DSM-5 criteria for OUD diagnosis. During the first few months of
the feasibility study, screening yielded few participants.
In fact, of more than four thousand patients screened,
except for self-referred patients, no new patients were
identified with a positive OUD screen. This finding is
surprising in light of other studies which have suggested
an approximately 1% prevalence of OUD among primary
care populations [15].
Clinics participating in the feasibility study varied in
their experience of screening, diagnosing, and treating
individuals with OUD. Among clinics that started universal screening specifically for the study, some reported
that a substantial proportion of primary care patients
declined an OUD screen, and care coordinators in these
clinics relayed patients’ complaints or dissatisfaction with
being asked sensitive questions as well as frustration with
repeat screens. During the early days of the feasibility
study, some primary care providers expressed confusion
regarding the process of OUD diagnosis, such as being
unsure about how to follow-up with patients who screen
negative despite clear risk for opioid misuse observed
clinically. Some also conveyed that even when providers
suspected patients may have unhealthy use of opioids,
some providers were uncomfortable discussing OUD
diagnoses with patients in anticipation of a negative reaction from patients. Some clinicians also reported that
some patients on long-term opioid therapy did not want
an OUD diagnosis recorded in their medical records.
These challenges suggest that rural clinicians may need
more support or training to be comfortable approaching
or starting conversations with patients exhibiting opioid
use problems, which is similar to what has been found
with primary care physicians broadly [16, 17].
Challenges implementing new interventions into primary care generally are well-documented (i.e., complexity of the intervention, ability to visualize how the new
practice fits into the clinic workflow, having enough time
to implement the practice, self-efficacy to implement
the practice) [18]; thus we can expect that at least some
of these challenges may be mitigated over time. While
additional clinical training and support may help increase
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the yield of screening as well as improve providers’ interactions with patients with OUD, other barriers, such
as stigma toward patients with OUD, likely will persist.
Addressing substance use stigma in the community and
healthcare settings and incorporating additional strategies that can reach individuals with OUD are vital steps
to efficiently identifying patients with OUD and linking
them to MOUD. In addition to support or training to
improve provider comfort, part of addressing stigma can
include supports to improve patient comfort discussing
opioid use and OUD with their healthcare providers.
Low TM referral rates

Over the first two months of the feasibility study, TM
referral was low, with only 6% of approximately 450
patients with diagnosed OUD being referred. While one
clinic with no X-waivered providers referred all patients
with OUD (once identified) to TM, few new patients with
OUD were identified in this clinic. Moreover, there were
variations regarding which patients clinics chose to refer
to TM. For example, TM referrals by one clinic with an
established OBOT program and many X-waivered providers were only made for clinically complex patients
(e.g., those not adhering to medication instructions).
Some clinics referred patients to the TM vendor for
behavioral health services only, and MOUD was still
managed by the local clinic’s providers. Among clinics
that were offering the TM option to all of their patients
with OUD, the majority of patients did not accept the
TM referral. One provider conveyed that some of their
patients may consider the opportunity to take a trip to
attend clinic visits (as opposed to staying at home) an
important social activity.
Clinic champions and coordinators responsible for
implementing TM perceived that low referral rates might
be related to lack of trust in the effectiveness of TM for
treatment of OUD and concerns that patients may have
suboptimal adherence to online therapy appointment
sessions. Rural residents have been characterized as generally distrusting outsiders [8], and patients may particularly have trust issues with an outside TM provider,
as opposed to distrust TM generally. These patients have
created strong relationships with their clinic providers
and being sent to a new unknown online company may
have caused hesitation. Some care coordinators also perceived that the lack of a private place at home to attend
appointments would prevent patients from engaging in
TM sessions. As reported by one care coordinator, several patients with OUD under drug court were required
to attend in-person services by their drug court judge.
The care coordinator reported an initial lack of support for MOUD in primary care by the courts and now,
with the introduction of TM, skepticism about the
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appropriateness of TM for court-referred patients. Season of the year was also reported as a possible reason for
low referral rates, as providers reported that patients are
more active in outdoor activities in the summer months.
These clinics speculated an increase in demand for TM
services will occur in the winter months (for those with
internet connectivity at home) because getting to the
clinic will be harder.
Digital device and internet access challenges

TM services require internet access and a device on
which a video application can be used but, according to
not only clinic providers and staff but also the TM vendor, many patients in rural areas do not have adequate
access to the internet or the needed mobile device with
adequate service data allowance that can support the use
of TM. The TM provider noted anecdotally that the digital access problem was particularly worse when public
WIFI sources (such as coffee shops and libraries) were
closed during the COVID-19 pandemic. One clinic also
reported that many of their patients are having trouble with the tablet (available in the clinic) for screening
because they have never used a touch screen device.
Lack of digital access could have implications for disparities in access to TM-based care. In one of our prior
studies [19] based on the 2019 national survey conducted by the Census, we found that disproportionally
higher rates of poor and racial/ethnic minorities (particularly American Indian or Alaska Native, black, and
Hispanic) in rural communities lacked either computers
or smartphones with internet connections. In addition,
gaps in technical skills to navigate various online platforms could also become a roadblock for TM uptake,
especially among patients with limited exposure to, or
experience with, technology. Although federal TM policy has focused on provider reimbursement and clinicians’ capacity to deliver care remotely, patients’ lack
of internet connectivity, appropriate devices, and digital skills remain problematic and, if unaddressed, may
lead directly to even greater health disparities, noticeably among those poor or racial/ethnical minorities who
already face many other disparities.
Workflow and capacity barriers

Despite efforts to assist clinics in developing standard operating procedures (SOP) that provide step-bystep descriptions and visualizations for how screening,
diagnosis and TM referral could be incorporated into
clinic workflows, some clinics in this early stage still
encountered difficulty implementing the new practices.
Throughout the first two months of the feasibility study,
clinics adjusted their workflows and procedures. For
example, one clinic started by having front desk staff
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conduct OUD screening in the lobby and later determined that having a nurse conduct the screening in an
exam room would be more comfortable for patients.
This change may have the potential to yield more positive screens. Two other clinics reported plans to schedule
patients to come in 15 min prior to their appointments to
complete screening.
There were also workflow and capacity challenges to
referral and coordination with the TM vendor during
early implementation. For example, some clinic staff were
unclear about TM referral procedures, perhaps suggesting the need for further training on new workflow procedures among the partner organizations. In addition, the
virtual handoff process usually requires a private room
in the clinic, adding burden to some clinics’ space management. Several clinics experienced long, unanticipated
wait times to set up an initial appointment for referred
patients with the TM vendor. During the COVID-19
pandemic, the study TM vendor’s service capacity was
further challenged by an influx of patients with mental
health symptoms and alcohol use. Additionally, many
clinic staff were working remotely, and some were furloughed, which also impacted early implementation. At
the start of COVID-19, most clinics limited in-person
visits and conducted remote telephone or televideo visits.
One clinic reported that although in-person visits have
gradually resumed in their clinic, social distancing continues to impose challenges to clinic workflows, including implementation of screening and TM referral.
Insurance coverage variability

To ensure TM can be covered by insurance including
Medicaid, the study requires that clinics accept Medicaid
and/or are in Medicaid expansion states. The study TM
vendor accepts almost all forms of insurance including
Medicaid. Nevertheless, there are many local Medicaid
carriers, and not all cover services provided by the study
TM vendor. One patient referred by a study clinic was
determined by the TM vendor to be “financially ineligible” because the patient’s Medicaid provider did not
cover the study TM vendor. Study investigators reached
out to the local authorities and facilitated the establishment of a TM contract with that particular insurance
provider. After this experience, team members discovered the same was true of a second Medicaid carrier and
repeated this process. Nevertheless, the complication of
local variations in insurance coverage for TM adds further challenges to TM access.

Conclusions
TM offers options and solutions to many barriers to
OUD care that rural communities face. The current study
aims to test a care coordination model based on referral
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and coordination between an external TM vendor and
primary care clinics; study design and procedures introduce new workflows for identifying individuals with
OUD, referring to TM, and tracking and documenting
these procedures. The early experiences and challenges
identified are largely related to establishing a new service
relationship (e.g., referral process), implementing new
study procedures (e.g., screening, diagnosis), as well as
structural barriers (digital access, insurance), particularly
in the context of the COVID-19 pandemic. As noted,
some of these challenges are clinic-specific, as these clinics were selected, by design, with diverse characteristics
(e.g., West vs. East coast location, number of prescribers).
Despite the challenges identified thus far, clinics participating in the feasibility study and the TM vendor are
working to address these barriers. We have observed that
many clinics now offer clinic space and devices for use by
patients lacking personal access. Some clinics are adjusting their screening procedures to provide greater privacy
as well as opportunities for questions and answers with
clinic staff regarding screening. Other clinics have spearheaded community outreach to attract more patients
with OUD to seek MOUD. The research team will continue to encourage/support clinics in community outreach activities, such as advertising TM accessibility at
community centers, churches, substance use specialty
care settings, and emergency departments, as well as
promoting the study via neighborhood social network
applications (e.g., NextDoor, Ring). The study team is also
planning additional provider training and technical assistance to ease the referral process, diagnosis challenges,
and engaging patients in OUD treatment and TM. Developing trust between clinics and an external TM vendor
is also essential for a successful care coordination model,
and this will take time and frequent communication. The
same is true for adding new procedures to clinical workflows and implementing a new study.
We summarize in Fig. 1 the different points in the
OUD care continuum addressed by the care coordination model, barriers experienced, and potential responses
based on preliminary lessons learned. Many of these
challenges may not be specific to rural communities,
but appear to have been exacerbated by vulnerabilities
unique to rural areas (e.g., digital access, social distress
and isolation) described earlier. Nevertheless, clinics and
providers participating in the feasibility study demonstrated a strong commitment to serve their patients and
communities, which is solid ground upon which to continue to improve treatment for people with OUD.
As noted, many TM restrictions have been waived due
to COVID-19. There are efforts [20] underway to allow
these waivers to continue even after the public health
emergency ends. Therefore, the movement to expand
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Fig. 1 Primary care-telemedicine (TM) care coordination model for treating people with OUD: early challenges and potential solutions

telemedicine is anticipated to grow even faster and more
widely in the near future. Nevertheless, while there have
been some non-experimental studies supporting the
effectiveness of TM [21], there still have been no randomized controlled trials demonstrating the effectiveness
of TM vs. in-person or other control conditions for treating OUD. This is an area in which expansion of services
or practices outpaces research, either by necessity (e.g.,
COVID-19) or logical evolution (logistical convenience).
There are many questions remaining as to best practices for including TM-based MOUD in primary care.
For example, which patients are appropriate for TM
referral? What is the best way for provider-patient
remote relationships to be developed and maintained?
What is the best model for TM? The current study
assesses a care coordination model that includes referral and coordination of TM in primary care, but there are
many other ways that TM can be delivered. In addition
to convenience and flexibility in care choices, empirical
investigations are needed to identify remote care models
that meet the variety of needs among patients for optimal
care.
In this commentary, we highlight our experiences and
challenges in the initial phase of our study, based on our
observations interacting with the rural primary care
clinics, with the hope of stimulating more questions
and investigations to improve the study and implementation of evidence-based TM care. The research team
is currently conducting focus groups and phone interviews with clinic leadership, providers, and staff as well

as patients, in order to more systematically identify and
understand barriers and facilitators of implementing
TM in primary care clinics. This line of inquiry should
lead to a better understanding of efficient implementation and delivery of quality TM care. With TM expanding rapidly, understanding implementation and proving
effectiveness are critical for ensuring the best care for
people with OUD.
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